Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme
Clinical trial NCT01648348 · COMPLETED
Trial details
- NCT number
- NCT01648348
- Sponsor
- National Cancer Institute (NCI)
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2012-11-01
- Primary completion
- 2016-05-11
- Enrollment
- 116
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.